OTCMKTS:PARD - Poniard Pharmaecuticals Stock Price, Price Target & More

$0.0470 +0.00 (+6.82 %)
(As of 04/26/2018 09:13 AM ET)
Previous Close$0.0440
Today's Range$0.0470 - $0.0759
52-Week Range$0.0430 - $0.1750
Volume8,900 shs
Average Volume4,832 shs
Market Capitalization$70,000.00
P/E RatioN/A
Dividend YieldN/A

About Poniard Pharmaecuticals (OTCMKTS:PARD)

Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.

Receive PARD News and Ratings via Email

Sign-up to receive the latest news and ratings for PARD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares1,500,000

How to Become a New Pot Stock Millionaire

Poniard Pharmaecuticals (OTCMKTS:PARD) Frequently Asked Questions

What is Poniard Pharmaecuticals' stock symbol?

Poniard Pharmaecuticals trades on the OTCMKTS under the ticker symbol "PARD."

Who are some of Poniard Pharmaecuticals' key competitors?

Who are Poniard Pharmaecuticals' key executives?

Poniard Pharmaecuticals' management team includes the folowing people:
  • Ronald A. Martell, Chairman of the Board (Age 54)
  • Robert S. Basso, Independent Director (Age 67)
  • Frederick B. Craves Ph.D., Independent Director (Age 70)
  • Carl S. Goldfischer M.D., Independent Director (Age 58)
  • Robert M. Littauer, Independent Director (Age 56)
  • David R. Stevens Ph.D., Independent Director (Age 67)

Has Poniard Pharmaecuticals been receiving favorable news coverage?

Media headlines about PARD stock have been trending positive on Thursday, according to Accern. Accern ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Poniard Pharmaecuticals earned a media sentiment score of 0.27 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 46.74 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Poniard Pharmaecuticals?

Shares of PARD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Poniard Pharmaecuticals' stock price today?

One share of PARD stock can currently be purchased for approximately $0.0470.

How big of a company is Poniard Pharmaecuticals?

Poniard Pharmaecuticals has a market capitalization of $70,000.00.

How can I contact Poniard Pharmaecuticals?

Poniard Pharmaecuticals' mailing address is 750 BATTERY STREET SUITE 330, SAN FRANCISCO CA, 98119-4114. The biopharmaceutical company can be reached via phone at 206-286-2501 or via email at [email protected]

MarketBeat Community Rating for Poniard Pharmaecuticals (PARD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  35 (Vote Outperform)
Underperform Votes:  30 (Vote Underperform)
Total Votes:  65
MarketBeat's community ratings are surveys of what our community members think about Poniard Pharmaecuticals and other stocks. Vote "Outperform" if you believe PARD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PARD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Poniard Pharmaecuticals (OTCMKTS:PARD) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 4/26/2016 forward)


Poniard Pharmaecuticals (OTCMKTS:PARD) Earnings History and Estimates Chart

Earnings by Quarter for Poniard Pharmaecuticals (OTCMKTS:PARD)

Poniard Pharmaecuticals (OTCMKTS PARD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/28/2011Q3 2011($2.56)ViewN/AView Earnings Details
8/12/2011Q2 2011($2.40)($2.64)ViewN/AView Earnings Details
5/13/2011Q1 2011($2.40)($2.44)ViewN/AView Earnings Details
3/30/2011Q4 2010($5.20)($3.40)ViewN/AView Earnings Details
11/9/2010Q3 2010($6.80)($5.36)ViewN/AView Earnings Details
8/9/2010Q2 2010($7.60)($5.56)ViewN/AView Earnings Details
5/10/2010Q1 2010($9.20)($10.04)ViewN/AView Earnings Details
3/8/2010Q4 2009($9.20)($12.80)ViewN/AView Earnings Details
11/3/2009Q3 2009($12.00)($11.52)ViewN/AView Earnings Details
8/4/2009Q2 2009($13.60)($11.36)ViewN/AView Earnings Details
5/5/2009Q1 2009($15.20)($13.84)ViewN/AView Earnings Details
3/16/2009Q4 2008($15.20)($16.24)ViewN/AView Earnings Details
10/30/2008Q3 2008($13.20)($14.24)ViewN/AView Earnings Details
7/31/2008Q2 2008($12.40)($14.60)ViewN/AView Earnings Details
5/6/2008Q1 2008($12.80)($11.52)ViewN/AView Earnings Details
2/28/2008Q4 2007($10.80)($11.20)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Poniard Pharmaecuticals (OTCMKTS:PARD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Poniard Pharmaecuticals (OTCMKTS PARD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 30.00%
Insider Trading History for Poniard Pharmaecuticals (OTCMKTS:PARD)

Poniard Pharmaecuticals (OTCMKTS PARD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)


Poniard Pharmaecuticals (OTCMKTS PARD) News Headlines

No headlines for this company have been tracked by MarketBeat.com

SEC Filings

Poniard Pharmaecuticals (OTCMKTS:PARD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Poniard Pharmaecuticals (OTCMKTS:PARD) Income Statement, Balance Sheet and Cash Flow Statement


Poniard Pharmaecuticals (OTCMKTS PARD) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.